Company intelligence / Profile preview
STADA Arzneimittel AG
Bad Vilbel, Hessen, Germanystada.com ↗
- Ownership
- Private
- Employees
- ~13183
- Development stage
- Commercial
01
Overview
STADA has a diverse portfolio of commercial products including generics, consumer healthcare products, and specialty pharmaceuticals. The company has received marketing authorization applications for AVT03 (a proposed denosumab biosimilar) in 2024[4].
- Therapeutic areas
- NephrologyOncologyEndocrinologyImmunologyHematologyDermatologyGastroenterologyOphthalmologyNeurology
- Modalities
- Small moleculesBiosimilars
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
Request access →03
Partnerships
Alvotech (for biosimilar candidates)Calliditas Therapeutics (for IgA Nephropathy therapy)Sanofi (consumer healthcare distribution)[1][5][10]
Beyond the preview
Go deeper on STADA Arzneimittel AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STADA Arzneimittel AG.